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ABSTRACT
Background: Smoking plays a role in the development of chronic diseases and causes substantial negative economic con-
sequences. This study was carried out to estimate the annual cost of smoking-related cardio-cerebrovascular and pulmonary
diseases in the population by taking into account the direct costs associated with such co-morbid conditions in Indonesia.
Methods: Meta-analysis using the Mix-Programme Software of the data of patients from university medical centers who were
active smokers for more than a year and more than 20-pack years or passive smokers for more than a year and diagnosed with
Coronary Heart Disease, Myocardial Infarction, Stroke, COPD, Chronic bronchitis, or Lung Cancer had been conducted. Annual
direct cost was taken into account using the Decision Analysis Tree Age Pro (=DATA) software; cost data related to health care
expenditure were derived from secondary data sources in Jakarta. In addition, Population Attributable Risk (PAR) for each co-
morbid conditions was calculated based on published epidemiological data from local and international journals.
Results: One-hundred and eighty-seven patients (96% male) satisfying the inclusion criteria, were analyzed, of whom confirmed
diagnosis of Stroke was amongst 29% of the patients, CHD 16%, Myocardial Infarction 16%, Lung Cancer 15%, COPD 17%, and
Chronic Bronchitis 7%. Mean direct annual cost was highest for Lung Cancer (Rp 51.6 million) followed by Myocardial infarction
(Rp 38.5 million) and CHD (Rp 37.8 million); PAR for various co-morbid conditions (based on variations in relative risk and
smoking prevalence estimates) were: Stroke ~16%-26%, CHD ~17%-27%, MCI ~ 22%-33%, Lung Cancer ~ 17%-26%, COPD ~
13%-21%, Chronic Bronchitis ~ 42%-59%.
Conclusions: Annual cost of smoking-related diseases in Indonesia has been estimated. The highest cost is for Lung Cancer. The
highest PAR is for Chronic Bronchitis.
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ABSTRAK
Estimasi pembiayaan per tahun penyakit terkait merokok di Indonesia
Latar belakang: Merokok berkaitan dengan kejadian berbagai penyakit kronis dengan konsekuensi ekonomi berupa biaya yang
sangat banyak. Penelitian ini bertujuan untuk mengestimasi biaya dampak merokok pada berbagai kondisi ko-morbid terkait
penyakit jantung, otak dan paru di masyarakat Indonesia.
Metode: Meta-analisis dengan Mix-Programme software pada data sekunder penderita penyakit jantung iskemik, infark miokard,
stroke, COPD, bronkitis kronis atau kanker paru dari Rumah Sakit Pendidikan Jakarta dengan kriteria : perokok aktif lebih 1 tahun
dan merokok lebih 20 pak/tahun atau perokok pasif lebih 1 tahun. Cost-analysis dengan Tree Age Pro (=DATA) software dilakukan
untuk membandingkan pengeluaran/biaya pengobatan per tahun menurut berbagai ko-morbid. Population Attributable Risk (PAR)
untuk kondisi ko-morbid merujuk perhitungan yang ada pada jurnal epidemiologi lokal maupun internasional.
Hasil: Seratus delapan puluh tujuh=187 pasien (96% laki-laki) memenuhi kriteria inklusi; diantaranya 29% pasien menderita
stroke, 16% penyakit jantung iskemik, 16% infark miokard, 15% kanker paru, 17% COPD, dan bronkitis kronis 7%. Rerata
pengeluaran biaya per tahun tertinggi adalah kanker paru (Rp 51,6 juta), diikuti penyakit jantung iskemik (Rp 37,8 juta); dan infark
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miokard (Rp 38,5 juta). PAR untuk masing-masing kondisi ko-
morbid sebagai berikut: stroke 16-26%, penyakit jantung
iskemik 17-27%, infark miokard 22-33%, kanker paru 17-
26%, COPD 13-21%, dan bronkitis kronis 42-59%.
Simpulan: Pengeluaran biaya per tahun tertinggi untuk pe-
nyakit terkait dampak merokok adalah kanker paru-paru dan
bila PAR terbesar pada bronkitis kronis.
INTRODUCTION
The number of smokers will increase mainly due to
expansion of the world’s population. By 2030 there will
be at least another 2 billion people in the world.1
Increasing number of smokers have markedly increasing
risks of multiple cancer, particularly lung cancer, and
are at far greater risk of coronary heart disease, strokes,
emphysema, and many other fatal or non-fatal diseases.1
In Indonesia, number of smokers increase due to in-
creasing of population. In 2005, proportion of adult
smokers is 31.5% (i.e. 62.2% are man and 1.3% wo-
man). 2 Related to this proportion and results of Indone-
sian Household Health Survey, there are markedly in-
creasing risks of smoking related diseases.2 World
Health Organization states that 6%-12% of yearly
health care costs in Western Europe can be attributed
to smoking.3 Most of the studies of the direct medical
costs of smoking in the United States conclude that
these costs make up 6%-8% of overall annual cost of
health care.4 ,5 ,6 Estimates of the cost burden is similar
in Canada (4%), Australia (6%) and Japan (4%).6 , 7
The human costs of smoking are substantial. Even with
its life-threatening and well known consequences, to-
bacco smoking continues to be the single greatest cause
of premature death, killing half of all people who
continue to smoke for most of their lives.8 Smoking has
been shown to increase morbidity and mortality and to
decrease quality of life. Serious complication that
smokers are at increased risk of developing include:
most cancer type, including lung, laryngeal, esophageal,
bladder, pancreatic, gastric, cervical and endometrial;
respiratory disorders like chronic obstructive pulmonary
disease and pneumonia.9,10 Cardiovascular diseases such
as atherosclerosis and coronary heart disease,9,12 and
reproductive effects such as stillbirth and low birth
weight.9
Although the exact percentage of costs related to
tobacco use may vary by country, it seems clear that
smoking causes substantial negative economic cones-
quences throughout the world. The World Health Orga-
nization projects that global annual economic costs of
tobacco use in United States alone will be $500 billion a
year by 2010.1
Burden of smoking-related diseases is never calculated
in Indonesia. This economic costs of tobacco is crucial11
to make a substantial health program. The objective of
this study is to estimate the annual economic cost of
smoking-related diseases as a reference for effective
smoking cessation program.
The objectives of this study is to estimate the annual
economic cost of smoking-related diseases - focused on:
a. Cardiocerebrovascular diseases (Myocard infarction,
stroke), b. Pulmonary diseases (Chronic bronchitis,
COPD), c. Lung cancer; Taking into account the direct
costs associated with smoking-related diseases as above
in the population in Indonesia; Calculation of PAR
(population attributable risk) for each targeted disease
will be performed.
METHODS
Using the cost-of-illness framework, calculation of
direct costs associated with smoking related diseases
during 2006. Study conducted in one year time horizon.
Male or female age 30–80 years, active smoking more
than one year and twenty pack-years or passive smoking
more than one year, diagnosed as cardiocerebrovascular
diseases (coronary heart diseases or myocard infarction)
or pulmonary diseases (Chronic Bronchitis, COPD) or
lung cancer.
Confirm diagnosed as cardiocerebrovascular or
pulmonary diseases related to others causative i.e.
congenital anomaly, work/environment pollution
(asbestosis, pneumoconiosis), etc.
Cost data related to health care expenditure are based on
direct costs of patient i.e. diagnostic costs, drugs costs,
physician fee, inpatient-stay costs and outpatient visit
costs. Direct cost accounted is average cost and within
interval of 95% CI.
Calculation of cost is simply by accounted from popu-
lation attributable risk (PAR) of each diseases times
direct cost.
Population attributable risk (PAR) of each diseases will
be calculated by formula (p(RR-1))/(p(RR-1)+1), which
p is proportion of smoking population in Indonesia and
relative risk or odds ratio (RR) of each diseases is
estimated by meta analysis of published local and
international journals.13-27
RESULTS
Artikel Asli Estimating The Annual Cost of Smoking-Related Diseases in Indonesia
Volume 43, Nomor 5, Tahun 2009 249
One hundred eighty seven patients recruited satisfying
the inclusion criteria. Ninety percentage of the patients
are man. Confirmed diagnosis of stroke was amongst
29% of the patients and chronis bronchitis was the
smallest percentage (7%). Table 1 provides detail of
patient distribution.
Mean total annual direct cost of smoking-related
diseases was Rp 27.6 million (range Rp 20.9 – 34.2
million), lowest total annual direct cost was Rp 0.43
million and the highest was Rp 379 million.
The highest mean total annual direct cost was for Lung
cancer: Rp 51.6 million (range Rp 28.1–75.2 million)
and the lowest mean total annual direct cost was for
chronic bronchitis: Rp 7.682 million (range Rp 5.315–
10 million). Table 2 provides detail of direct cost for
each disease.
Calculation of Relative Risk from metaanalysis
presented in table 3. Highest RR was myocardial
infarction: 3.50 (2.09;5.87), lowest RR was lung cancer:
1.53 (1.44;1.62). Highest PAR value also was on
myocardial infarction: 44.06% (25.56%;60.54%), it
means if smoking habit reduce will decrease burden of
myorcardial infarction in Indonesia population by
44.06%. The lowest PAR value was lung cancer:
14.24% (12.25%;16.23%).
Table 1. Proportion distribution of smoking-related diseases
Disease Total (N=187)n %
Stroke 54 28.88
Lung Cancer 28 14.97
Myocard infaction 30 16.04
Coronary Heart Disease 30 16.04
Chronic Bronchitis 14 7.49
COPD 31 16.58
Table 2. Mean total annual direct cost for each disease
Disease Cost (Rupiah)Mean 95% CI Minimum Maximum
Stroke 7.954.219 (5.224.813;10.700.000) 472.900 54.500.000
Lung Cancer 51.600.000 (28.100.000;75.200.000) 6.092.500 287.000.000
Infark Miokard 38.500.000 (24.700.000;52.200.000) 3.810.072 147.000.000
Coronary Heart Disease 37.800.000 (22.700.000;52.900.000) 4.868.457 180.000.000
Chronic Bronchitis 7.682.193 (5.315.018;10.000.000) 3.582.900 17.700.000
COPD 28.600.000 (2.488.615;54.800.000) 4.569.350 379.000.000
Total 27.600.000 (20.900.000;34.200.000) 472.900 379.000.000
Table 3. Relative risk dan population attributable risk of smoking-related diseases
Disease RR† 95% CI PAR‡ 95% CI RR
Stroke 1.54 (1.47;1.61) 14.54 (12.94;16.14)
Lung Cancer 1.53 (1.44;1.62) 14.24 (12.25;16.23)
Myocardial infarction 3.50 (2.09;5.87) 44.06 (25.56;60.54)
Coronary Heart Disease 1.63 (1.57;1.69) 16.52 (15.27;17.77)
Chronic Bronchitis 3.34 (2.46;4.52) 42.38 (31.49;52.60)
COPD 2.77 (1.86;4.12) 35.76 (21.26;49.58)
†RR Relative risk (meta-analysis)
‡PAR : Population attributable risk
Having the mean total direct cost of smoking-related
disease and PAR value, we can calculate estimated
saving cost by smoking cessation. Table 4 provides
detail of the estimated cost. Event avoided of
myocardial infarction was the highest estimated saving
cost: Rp 1,696 million (Rp 984 million; Rp 2,330
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million) and chronic bronchitis was the lowest: Rp 115
million (Rp 102 million; Rp 128 million).
The tables 5, 6, 7, and 8 provide detail of mean direct
cost based on cost type and mean direct cost based on
type of cost and type of disease. From the figure 1 we
can see that the highest PAR is in MI (44.06%) and its
estimated saving cost is Rp 1.69 billion. The second
highest PAR is chronic bronchitis (42.38%) with its
estimated saving cost as Rp. 326 million.
Table 4. Estimated saving cost by 100 cases for each smoking-related disease
Disease Estimated saving cost by 100 cases (Rupiah)
Stroke 115.632.224 (102,955,852;128,381,861)
Lung Cancer 734.633.042 (631,876,933;837,396,385)
Myocardial infarction 1.696.153.846 (984,030,595;2,330,692,962)
Coronary Heart Disease 624.267.085 (577,098,748;671,677,425)
Chronic Bronchitis 325.575.547 (241,892,091;404,090,318)
COPD 1.022.668.114 (607,951,699;1,418,053,473)
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Figure 1. Comparison between direct costs, PAR and estimated saving costs
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Table 5. Mean direct cost based on cost type
Type of cost ALL Diseases (in Rupiah)                                     ALL (COST in rupiah)Mean 95% CI Mean Minimum Maximum
Diagnostic 3.167.936 (2.435.483;3.900.390) 65.000 41.800.000
Laboratorium 1.775.934 (1.191.370;2.360.498) 30.000 39.200.000
Radiology 1.473.495 (1.154.775;1.792.214) 45.000 13.000.000
Treatment 16.000.000 (11.900.000;20.000.000) 92.745 220.000.000
Hospitalization 5.429.643 (3.968.817;6.890.469) 25.000 59.600.000
Investigation 2.023.035 (1.442.536;2.603.534) 65.000 38.000.000
Inpatient 17.900.000 (11.600.000;24.100.000) 83.574 371.000.000
Outpatient 9.968.618 (6.190.136;13.700.000) 160.000 182.000.000
Total (ALL) 27.600.000 (20.900.000;34.200.000) 472.900 379.000.000
Treatment was the second highest mean direct cost based on cost type. Inpatient hospitalization was the highest one.
Table  6. Mean direct cost based on type of cost  and type of disease
Type of cost STROKE (in  rupiah) LUNG CANCER  (in rupiah)Mean (95% CI mean) Minimum Maximum Mean (95% CI mean) Minimum Maximum
Diagnostic 1.927.198 (1.333.535;2.520.861) 240.000 10.900.000 8.592.971 (5.903.861;11.300.000) 1.011.500 33.800.000
Laboratorium 1.405.740 (807.632;2.003.847) 117.000 10.300.000 3.393.293 (1.546.114;5.240.471) 478.500 20.800.000
Radiology 693.320 (503.483;883.157) 45.000 3.800.000 5.199.679 (3.893.019;6.506.338) 219.000 13.000.000
Treatment 3.355.869 (1.894.524;4.817.214) 92.745 29.600.000 27.900.000 (11.200.000;44.600.000) 2.391.000 220.000.000
Hospitalization 3.469.410 (2.169.145;4.769.675) 25.000 17.300.000 15.200.000 (8.446.021;21.900.000) 310.000 59.600.000
Early Investigation 945.374 (805.990;1.084.757) 280.500 2.613.050 4.654.898 (3.256.351;6.053.445) 424.000 10.800.000
Inpatient 7.482.057 (4.676.859;10.300.000) 152.900 54.500.000 41.300.000 (25.200.000;57.400.000) 4.321.000 165.000.000
Outpatient 182.000.000 182.000.000
Total (ALL) 7.954.219 (5.224.813;10.700.000) 472.900 54.500.000 51.600.000 (28.100.000;75.200.000) 6.092.500 287.000.000
Table 7. Mean direct cost based on type of cost  and type of disease
Type of cost MYOCARDIAL INFARCTION  (in rupiah) CHD  ( in rupiah)Mean (95% CI mean) Minimum Maximum Mean (95% CI mean) Minimum Maximum
Diagnostic 3.495.367 (696.449;6.294.285) 100.000 41.800.000 2.491.967 (1.016.878;3.967.056) 65.000 21.400.000
Laboratorium 2.639.633 (6.315;5.272.951) 30.000 39.200.000 1.676.034 (278.631;3.073.438) 173.000 19.600.000
Radiology 855.733 (424.652;1.286.814) 70.000 4.380.000 871.800 (546.542;1.197.058) 60.000 3.405.000
Treatment 30.400.000 (17.700.000;43.000.000) 61.852 68.000.000 28.600.000 (17.000.000;40.300.000) 298.699 27.100.000
Hospitalization 4.592.502 (2.362.576;6.822.427) 225.000 29.100.000 6.675.059 (2.584.309;10.800.000) 340.000 43.600.000
Early investigation 2.016.744 (622.963;4.656.451) 65.000 38.000.000 658.937 (489.541;828.334) 71.663 1.368.874
Inpatient 9.480.056 (4.273.832;14.700.000) 332.160 59.800.000 9.306.074 (3.493.925;15.100.000) 83.574 66.600.000
Outpatient 11.000.000 (8.509.826;13.500.000) 160.000 24.600.000 8.313.758 (5.968.493;10.700.000) 176.427 27.000.000
Total (ALL) 38.500.000 (24.700.000;52.200.000) 3.810.072 147.000.000 37.800.000 (22.700.000;52.900.000) 4.868.457 180.000.000
Table 8. Mean direct cost based on type of cost  and type of disease
Type of cost CHRONIC BRONCHITIS   ( in rupiah) COPD  (in rupiah)Mean (95% CI mean) Minimum Maximum Mean (95% CI mean) Minimum Maximum
Diagnostic 1.981.571 (1.629.254;2.333.888) 1.277.500 3.748.500 1.198.717 (1.022.310;1.375.123) 460.000 2.300.000
Laboratorium 860.214 (719.320;1.001.109) 516.500 1.209.500 518.917 (443.466;594.368) 159.500 1.123.000
Radiology 1.121.357 (833.514;1.409.200) 619.000 2.770.000 679.800 (524.573;835.027) 145.000 1.885.000
Treatment 4.400.979 (2.481.263;6.320.695) 1.425.400 13.000.000 4.096.245 (3.322.307;4.870.183) 213.938 10.800.000
Hospitalization 1.299.643 (930.756;1.668.530) 700.000 2.995.000 873.143 (489.225;1.257.061) 170.000 4.200.000
Early investigation 2.050.371 (1.546.194;2.554.549) 913.000 4.103.400 2.294.398 (1.404.854;3.183.943) 612.300 9.794.000
Inpatient 63.000.000 (28.800.000;155.000.000) 3.591.403 371.000.000
Outpatient 5.631.821 (3.565.595;7.698.048) 2.082.900 15.300.000 5.533.867 (4.687.376;6.380.357) 3.622.600 12.000.000
Total (All) 7.682.193 (5.315.018;10.000.000) 3.582.900 17.700.000 28.600.000 (2.488.615;54.800.000) 4.569.350 379.000.000
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Table 6, 7, and 8 showed that the highest animal cost of
smoking-related diseases in Indonesia was lung cancer.
DISCUSSION
Estimated annual cost of smoking-related diseases have
been calculated. The highest cost was for myocardial
infarction. Table 5 provides total annual economic
burden by govenment for one patient suffer from
smoking-related disease; Rp 27.6 million. If there are
100 patients the cost will be Rp 2.7 billion. As a big
population country, health care cost attributed to
smoking will be huge. Detail of cost burden for each
disease presented on table 6, 7, 8 and 9. This
information can be used as a basis for cost effectiveness
analysis of smoking cessation program to reduce
smoking-related diseases.
CONCLUSIONS
Estimating annual cost of smoking-related diseases have
been calculated for cardiocerebrovascular diseases (MI,
CHD, Stroke) and pulmonary diseases (Chronic
bronchitis, COPD, Lung cancer). Mean estimated
annual cost of MI: Rp 38.5 million (24.7 million; 52.2
million). Mean estimated annual cost of CHD: Rp 37.8
million (22.7 million; 52.9 million). Mean estimated
annual cost of Stroke: Rp 7.954 million (5.224 milllion;
10.7 million). Mean estimated annual cost of Lung
cancer: Rp 51.6 million (28.2 million; 75.2 million).
Mean estimated annual cost of Chronic bronchitis: Rp
7.682 million (5.315 million; 10 million). Mean
estimated annual cost of COPD: Rp 28.6 million (2.488
million; 54.8 million). Total economic burden for
smoking-related disease was Rp 27.6 million (20.9
million; 34.2 million). PAR value for MI 44.06%; CHD
14.54%; Stroke 14.54%; Lung cancer 14.24%; Chronic
bronchitis 42.38%; COPD 35.76%.
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